Di­al­ing down the tox­ic ef­fects of ra­di­a­tion on can­cer pa­tients, Galera gets break­through sta­tus on Phase IIb da­ta

A biotech­nol­o­gy com­pa­ny near Philadel­phia — armed with da­ta from a Phase IIb tri­al — just got break­through sta­tus from the FDA for a drug that might …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.